You have to hand it to Trump. Mostly he is totally in bed with big business, but he knows when to throw an industry under the bus.
Big Pharma is monumentally unpopular, and for good reason. Trump’s first gambit was to require companies to mention the price of a drug in their ads. That fell flat; drugs have multiple prices—another defect of our lunatic, hyper-commercialized system.
So now Trump has moved to benchmarking drug prices charged to Americans against those charged to health systems overseas. That’s a nice headline grabber on the eve of the midterms, but don’t hold your breath. Once the elections are over, Trump’s demagoguery will move on to something else.
If Trump were serious, he would take steps to change the law and allow Medicare to negotiate bulk discounts with drug companies. He is deadly serious of course—just not about helping consumers.